PKM2 inhibitor (compound 3k): Selective Disruption of Tumor Metabolism

Executive Summary: PKM2 inhibitor (compound 3k) is a potent, selective inhibitor of pyruvate kinase M2 (PKM2), a key enzyme in the glycolytic pathway highly expressed in many cancers (APExBIO). It exhibits an IC₅₀ of 2.95 μM against PKM2, with nanomolar antiproliferative activity in PKM2-overexpressing cancer cell lines (HCT116, Hela, H1299) (Wu et al., 2025). Oral administration in SK-OV-3 ovarian cancer xenograft mice results in significant tumor volume reduction without major organ toxicity. The compound's selectivity profile demonstrates greater cytotoxicity in cancer versus normal cells. These features position compound 3k as a promising metabolic inhibitor for tumor-specific therapies targeting glycolysis.

Biological Rationale

Pyruvate kinase M2 (PKM2) is a rate-limiting enzyme in glycolysis, catalyzing the conversion of phosphoenolpyruvate to pyruvate, generating ATP (Wu et al., 2025). PKM2 is predominantly expressed in proliferating cells, including cancer cells, and supports the Warburg effect—preferential aerobic glycolysis despite oxygen availability (Targeting PKM2 in Cancer and Beyond). Tumor cells rely on PKM2-mediated glycolytic reprogramming for rapid energy production, biosynthetic precursor generation, and cell survival. Selective inhibition of PKM2 disrupts this metabolic adaptation, reducing cancer cell viability and tumor progression.

Mechanism of Action of PKM2 inhibitor (compound 3k)

PKM2 inhibitor (compound 3k) binds selectively to PKM2, inhibiting its catalytic activity with an IC₅₀ of 2.95 μM under cell-free enzymatic assay conditions (APExBIO). Inhibition of PKM2 blocks the conversion of phosphoenolpyruvate to pyruvate, curtailing ATP production via glycolysis. This results in decreased lactate output and a metabolic shift away from aerobic glycolysis. In cancer cells, this metabolic stress induces cell cycle arrest and may trigger autophagic cell death, particularly in lines with high PKM2 expression (PKM2 Inhibitor (Compound 3k): A Novel Strategy). Compound 3k does not significantly inhibit pyruvate kinase isoforms expressed in normal cells, conferring tumor cell selectivity.

Evidence & Benchmarks

• Compound 3k inhibits PKM2 enzymatic activity with an IC₅₀ of 2.95 μM (in vitro, cell-free assay) (APExBIO).
• Exhibits antiproliferative activity in cancer cell lines: HCT116 (IC₅₀ = 0.18 μM), Hela (IC₅₀ = 0.29 μM), H1299 (IC₅₀ = 1.56 μM) under 72 h culture conditions (Wu et al., 2025).
• Shows preferential cytotoxicity for PKM2-overexpressing cancer cells versus normal BEAS-2B cells (cell viability assay) (APExBIO).
• Reduces tumor volume and weight in SK-OV-3 xenograft-bearing BALB/c nude mice (oral, 5 mg/kg every 2 days, 31 days), with no significant body weight loss or major organ toxicity (in vivo efficacy study) (Wu et al., 2025).
• In macrophage polarization models, PKM2 inhibitor reverses pro-inflammatory effects of USP7 knockdown, confirming PKM2 dependence in metabolic reprogramming (Wu et al., 2025).

This article extends prior coverage by integrating head-to-head efficacy data, selectivity parameters, and in vivo benchmarks not detailed in Precision Targeting of Tumor Metabolism, which focused on conceptual applications beyond oncology.

Applications, Limits & Misconceptions

PKM2 inhibitor (compound 3k) is primarily indicated for preclinical research on tumor metabolism and glycolytic pathway inhibition. It is used in:

• Cell viability and proliferation assays in cancer research (Reliable Cancer Cell Assays).
• In vivo xenograft models for evaluating metabolic inhibitors.
• Studies exploring autophagic and apoptotic cell death in response to glycolytic stress.
• Investigation of immunometabolic regulation, including macrophage polarization (Wu et al., 2025).

Common Pitfalls or Misconceptions

• Compound 3k does not inhibit PKM1 or other PK isoforms at comparable concentrations; effects are PKM2-specific.
• It is not suitable for direct therapeutic use in humans; for research use only.
• Long-term DMSO solutions may degrade; fresh preparation is recommended.
• Ineffective in tumors lacking PKM2 overexpression; expression profiling is advised before use.
• Not water- or ethanol-soluble; improper solvent selection undermines reproducibility.

Workflow Integration & Parameters

PKM2 inhibitor (compound 3k) is supplied by APExBIO (SKU B8217) as a solid (MW 345.48, C₁₈H₁₉NO₂S₂). Solubilize at ≥34.5 mg/mL in DMSO with gentle warming; insoluble in ethanol or water. Store powder at -20°C; avoid long-term storage of solutions (product page). For cell culture, dilute DMSO stocks to ≤0.1% v/v final concentration. For animal studies, administer orally at 5 mg/kg every other day for up to 31 days, monitoring weight and organ histology. For assay design, refer to Reliable Cancer Cell Assays for best practices in cytotoxicity and proliferation endpoints.

Conclusion & Outlook

PKM2 inhibitor (compound 3k) is a benchmark tool for dissecting cancer cell metabolism and glycolytic pathway dependence. Its selectivity, potency, and in vivo efficacy in xenograft models substantiate its role in translational oncology and immunometabolism research. Future work will clarify its mechanisms in autophagic cell death and immune cell polarization, with implications for next-generation cancer therapies targeting metabolic vulnerabilities (PKM2 Inhibition as a Cornerstone Strategy). Researchers should always verify PKM2 expression in target models and adhere to recommended preparation and storage protocols to ensure data reliability.